Moomoo AIのまとめ
Heart Test Laboratories, a medical technology company, has not provided specific financial performance metrics such as revenue, operating profit, net profit, or diluted earnings per share in its latest quarterly report. However, the company has disclosed stock-based compensation for stock options, which increased from $149,153 in the nine months ended January 31, 2023, to $326,578 in the same period in 2024. Deferred tax assets have also been reported, with a net operating loss carryforwards of approximately $52 million as of January 31, 2024, up from $46 million the previous year. The company has entered into significant business development agreements, including a multi-year collaboration with Rutgers University and multiple definitive license agreements with Mount Sinai for AI cardiovascular algorithms. Heart Test Laboratories plans to submit a 510(k) FDA submission for its MyoVista device and is aiming for clearance within the 2024 calendar year. The company has also received patent allowances in various regions and has entered into financial agreements to support its operations, including an Equity Distribution Agreement with Maxim Group LLC.
Heart Test Laboratories, a medical technology company, has not provided specific financial performance metrics such as revenue, operating profit, net profit, or diluted earnings per share in its latest quarterly report. However, the company has disclosed stock-based compensation for stock options, which increased from $149,153 in the nine months ended January 31, 2023, to $326,578 in the same period in 2024. Deferred tax assets have also been reported, with a net operating loss carryforwards of approximately $52 million as of January 31, 2024, up from $46 million the previous year. The company has entered into significant business development agreements, including a multi-year collaboration with Rutgers University and multiple definitive license agreements with Mount Sinai for AI cardiovascular algorithms. Heart Test Laboratories plans to submit a 510(k) FDA submission for its MyoVista device and is aiming for clearance within the 2024 calendar year. The company has also received patent allowances in various regions and has entered into financial agreements to support its operations, including an Equity Distribution Agreement with Maxim Group LLC.
医療技術企業であるHeart Test Laboratoriesは、最新の四半期報告書において、売上高、営業利益、純利益、濃縮希釈後の一株当たり利益など、具体的な財務パフォーマンス指標を提供していません。ただし、同社はストックオプションのストックベース報酬を開示しており、2023年1月31日までの9ヶ月間に$149,153から2024年の同期間には$326,578に増加しました。また、2024年1月31日時点で約5200万ドルの純営業損失持ち越しを報告しています。前年は4600万ドルでした。同社はRutgers Universityとの多年にわたる協力関係や、AI心血管アルゴリズムのライセンス...すべて展開
医療技術企業であるHeart Test Laboratoriesは、最新の四半期報告書において、売上高、営業利益、純利益、濃縮希釈後の一株当たり利益など、具体的な財務パフォーマンス指標を提供していません。ただし、同社はストックオプションのストックベース報酬を開示しており、2023年1月31日までの9ヶ月間に$149,153から2024年の同期間には$326,578に増加しました。また、2024年1月31日時点で約5200万ドルの純営業損失持ち越しを報告しています。前年は4600万ドルでした。同社はRutgers Universityとの多年にわたる協力関係や、AI心血管アルゴリズムのライセンス契約を含む重要なビジネス開発契約に参画しています。Heart Test Laboratoriesは、MyoVistaデバイスの510（k）FDA申請を行い、2024年のカレンダーでの承認を目指しています。同社は、さまざまな地域で特許を受け、Maxim Group LLCとのエクイティ・ディストリビューション契約をはじめとする、運営を支援するための財務契約にも参画しています。
役に立った
役に立たない